APEX-Agents · Management Consulting

World112-1_Task03_NA

10/10Pass

APEX-Agents task World112-1_Task03_NA in AI Agents for FDA and Pharma Promotional Compliance. Compare dual-harness agent runs across models — rubric criteria, scores, and public traces.

AI Agents for FDA and Pharma Promotional ComplianceManagement Consulting World 112.1Dual harnessGrader: rubric

Task IDtask_0c527e11cc1c436696561a15eead68b2

WorldManagement Consulting World 112.1

Expected outputmessage_in_console

Published runs5 models · dual config

Task prompt

What the agent was asked to do

Analyze the attached report and the continuous manufacturing report to state the FDA-encouraged manufacturing style that differs from traditional methods which is mentioned in both reports. Using the site-level KPI files and the savings percentages from the reports (using midpoints for ranges), calculate the 2024 YTD potential savings for Impact across Materials, Labor, and Overhead by shifting to this approach. Use "maintenance" savings for overhead if not specified. Next, using Impact's P&L, calculate the dollar value of a 20% reduction in US 2024 COGS (note that PnL values are in $Ks). Determine if the total estimated savings from above exceed this value. Additionally, state if any category-level savings exceed 10% of total US 2024 COGS. Finally, using the reports, cite two North America or EMEA-based pharma companies using this manufacturing style and state any reported cost reductions. Return all findings to me in here as a single message. Round output currency values to the nearest cent, but do not round intermediate steps.

Published trajectories

Agent runs on this task

Curated dual-harness runs (parsed + original sandbox). Best scored run per model.

Model	Harness	Score	Result	Links
GPT-5.5showcase	dual	10/10	Pass	Share page Public trace
Gemini 3.1 Pro	dual	10/10	Pass	Share page Public trace
GPT-5.4	dual	10/10	Pass	Share page Public trace
GPT-5.4 mini	dual	10/10	Pass	Share page Public trace
GPT-5.4 nano	dual	10/10	Pass	Share page Public trace

Grading rubric

Criteria and grader verdict (showcase run)

States that Continuous Manufacturing represents a significant change from initial manufacturing methodology in the pharmaceutical industry and is encouraged by the FDA
Pass
Evidence: TEXT_RESPONSE says “The shared FDA-encouraged approach is **continuous manufacturing (CM)**, as opposed to traditional batch manufacturing” and FDA has “long championed” CM. Assessment: Criterion asks states CM represents significant change from initial/traditional methodology and is encouraged by FDA; pass because response clearly identifies CM as differing from traditional batch and FDA-encouraged.
States that the potential 2024 US material cost savings for Impact by switching to continuous manufacturing is $274,203,900.00
Pass
Evidence: Savings table in TEXT_RESPONSE lists Materials estimated 2024 YTD savings as “$274,203,900.00.” Assessment: Criterion asks states potential 2024 US material cost savings is $274,203,900.00; pass exact value stated.
States that the potential 2024 US labor cost savings for Impact by switching to continuous manufacturing is $205,819,152.50
Pass
Evidence: Savings table in TEXT_RESPONSE lists Labor estimated 2024 YTD savings as “$205,819,152.50.” Assessment: Criterion asks states potential 2024 US labor cost savings is $205,819,152.50; pass exact value stated.
States that the potential 2024 US overhead cost savings for Impact by switching to continuous manufacturing is $143,888,800.00
Pass
Evidence: Savings table in TEXT_RESPONSE lists Overhead estimated 2024 YTD savings as “$143,888,800.00.” Assessment: Criterion asks states potential 2024 US overhead cost savings is $143,888,800.00; pass exact value stated.
States that Impact's COGS savings target of 20% of Impact's US 2024 COGS is $516,598,800
Pass
Evidence: TEXT_RESPONSE under “20% US 2024 COGS comparison” states “20% reduction in US 2024 COGS = $516,598,800.00.” Assessment: Criterion asks states Impact's COGS savings target of 20% of US 2024 COGS is $516,598,800; pass (same value with cents formatting).
States that the total estimated savings from switching to continuous manufacturing exceed 20% of Impact US 2024 COGS
Pass
Evidence: TEXT_RESPONSE states “Estimated CM savings = $623,911,852.50” and “Yes — the estimated CM savings exceed a 20% reduction in US 2024 COGS.” Assessment: Criterion asks states total estimated savings exceed 20% of Impact US 2024 COGS; pass, clearly stated.
States that a category that would exceed 10% of the US 2024 COGS total in savings is Materials
Pass
Evidence: TEXT_RESPONSE category table shows Materials “$274,203,900.00,” “10.62%,” and “Exceeds 10%... **Yes**,” while Labor/Overhead are No. Assessment: Criterion asks states a category exceeding 10% of US 2024 COGS total savings is Materials; pass.
States that a company with notable facilities using continuous manufacturing is Genentech
Pass
Evidence: TEXT_RESPONSE North America/EMEA examples include “**Genentech — North America / South San Francisco:** ... large-scale CM implementation.” Assessment: Criterion asks states a company with notable facilities using continuous manufacturing is Genentech; pass.
States that a company with notable facilities using continuous manufacturing is Biogen
Pass
Evidence: TEXT_RESPONSE North America/EMEA examples include “**Biogen — EMEA / Denmark facility:** ... successfully implemented continuous manufacturing.” Assessment: Criterion asks states a company with notable facilities using continuous manufacturing is Biogen; pass.
States that Genentech's manufacturing cost reduction with continuous manufacturing is 35%
Pass
Evidence: TEXT_RESPONSE says Genentech achieved “a 35% reduction in manufacturing costs.” Assessment: Criterion asks states Genentech's manufacturing cost reduction with continuous manufacturing is 35%; pass exact percentage stated.